The Life Sciences Report

"BTI's Transcend platform is a huge financial incentive to the owner of the therapy because it could greatly extend the drug's exclusivity." (5/16/13) biOasis Technologies Inc. - The Life Sciences Report Interview with William Gregozeski More >

"ATHX is a neat little company that has a great management team and deep science bench." (5/10/13) Athersys Inc. - The Life Sciences Report Interview with Jason Kolbert More >

"MSLP was growing very fast, and it had significant events that made it possible for us to raise $12M for it." (4/25/13) MusclePharm Corp. - The Life Sciences Report Interview with Richard Huebner More >

"What's particularly exciting about VNRX is that it believes its technology is able to identify targeted cancers in stage 1 and stage 2." (4/25/13) VolitionRx Ltd. - The Life Sciences Report Interview with Dick Huebner More >

"ATHX's partnership with Pfizer Inc. puts it in a remarkable position." (4/11/13) Athersys Inc. - The Life Sciences Report Interview with Steve Brozak More >

"CYTR's preclinical data for aldoxorubicin has been very supportive, and its phase 1b/2 trial has shown quite promising, albeit early stage, efficacy." (6/13/13) CytRx Corp. - The Life Sciences Report Interview with Michael Aikenhead More >

"ATHX is an exciting story and definitely a company to watch." (6/6/13) Athersys Inc. - The Life Sciences Report Interview with Christian Glennie More >

"NEO has been able to continue to grow the topline nicely and maintain margins of more than 45%." (5/30/13) NeoGenomics Laboratories - The Life Science Report with Kevin DeGeeter More >

"OPK's 4Kscore is approved in Europe and should be approved in the U.S. sometime in 2013." (5/30/13) OPKO Health Inc. - The Life Science Report with Kevin DeGeeter More >

"CTH is very early in the game with a very good and relatively derisked idea." (5/30/13) Cynapsus Therapeutics Inc. - The Life Science Report with Ori Hershkovitz More >